News

MHRA issues new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca and extremely rare, unlikely to occur blood clots

MHRA not recommending age restrictions in COVID-19 Vaccine AstraZeneca vaccine use

Updated information is being provided for people and healthcare professionals on the possible risk of extremely rare and unlikely to occur specific types of blood clots following vaccination with the COVID-19 Vaccine AstraZeneca, the Medicines and Healthcare products Regulatory Agency ... Read more

EMA Statement: AstraZeneca COVID-19 Vaccine

Benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets

EMA’s safety committee, PRAC, concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting of 18 March 2021. Read more

Featured News Sources

Can't find what you're looking for? Try browsing our Featured News Sources. You can also find new previously featured on our home page in our News Archive! Read more

E-Learning

Featured
Global Health Trials

Pharmacovigilance

This module from the Toolkit for research and development of paediatric antiretroviral drugs and formulations introduces the concepts of pharmacovigilance and adverse drug reactions, discusses the burden of adverse drug reactions for children and explains the importance of pharmacovigilance in the context of antiretroviral therapy.

Articles

Featured
IDDO

Medicine Quality Monitoring Globe

by Global Pharmacovigilance

The problem of substandard and falsified (SF) medical products affects all countries but few regulatory authorities or pharmaceutical companies have policies of publicly releasing data. In order to fill the ...